← back to search

Corinne Vandermeulen

KU Leuven · BE
Area of research
Health · Epidemiology
Research interest
Research interests include Medicine, Immunogenicity, Vaccination, Reactogenicity, Adverse effect, and Pharmacology.
h-index
citations
989
works
13
NIH funding
primary concept
email

Recent publications

Host immune response to respiratory syncytial virus infection and its contribution to protection and susceptibility in adults: a systematic literature review
Expert Review of Clinical Immunology 2025cited by 9position: middledoi
Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial
The Journal of Infectious Diseases 2022cited by 117position: middledoi
Age-dependent seroprevalence of SARS-CoV-2 antibodies in school-aged children from areas with low and high community transmission
European Journal of Pediatrics 2021cited by 45position: lastdoi
Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27–45 years of age compared to women 16–26 years of age: An open-label phase 3 study
Vaccine 2021cited by 38position: middledoi
A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate
Nature 2020cited by 189position: middledoi
Immunogenicity and Safety of the 9-Valent Human Papillomavirus Vaccine in Solid Organ Transplant Recipients and Adults Infected With Human Immunodeficiency Virus (HIV)
Clinical Infectious Diseases 2020cited by 42position: lastdoi
Safety and immunogenicity of non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine
Vaccine 2019cited by 40position: middledoi
Attitudes, believes, determinants and organisational barriers behind the low seasonal influenza vaccination uptake in healthcare workers – A cross-sectional survey
Vaccine 2018cited by 97position: lastdoi
<sup>18</sup>F-JNJ-64413739, a Novel PET Ligand for the P2X7 Ion Channel: Radiation Dosimetry, Kinetic Modeling, Test-Retest Variability, and Occupancy of the P2X7 Antagonist JNJ-54175446
Journal of Nuclear Medicine 2018cited by 91position: middledoi
Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers
Cephalalgia 2018cited by 45position: middledoi
Phase I, Randomized, Double‐blind, Placebo‐controlled, Single‐dose, and Multiple‐dose Studies of Erenumab in Healthy Subjects and Patients With Migraine
Clinical Pharmacology & Therapeutics 2017cited by 96position: middledoi
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers
Frontiers in Pharmacology 2017cited by 64position: middledoi
Influenza and pertussis vaccination coverage in pregnant women
Vaccine 2015cited by 116position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

Mathieu Roelants · KU Leuven4 papers (2015–2021)Jan de Hoon · KU Leuven4 papers (2017–2018)Lise Boey · KU Leuven3 papers (2018–2021)Anne Van Hecken · KU Leuven3 papers (2017–2018)Gabriel Vargas · Amgen (United States)2 papers (2017–2018)Iris De Ryck · Global Vaccines (United States)1 papers (2019–2019)Erik Jongert · GlaxoSmithKline (Switzerland)1 papers (2025–2025)Nancy Dezutter · GlaxoSmithKline (Belgium)1 papers (2022–2022)Lode Godderis · KU Leuven1 papers (2018–2018)Els Duysburgh · KU Leuven1 papers (2021–2021)Steven M. Varga · University of Iowa1 papers (2025–2025) · 1 papers (2022–2022)Nathalie De Schrevel · GlaxoSmithKline (Belgium)1 papers (2022–2022)Edward Kerwin · Novartis (Switzerland)1 papers (2022–2022) · 1 papers (2022–2022)Roland Devlieger · Universitair Ziekenhuis Leuven1 papers (2015–2015)Isabel Leroux‐Roels · Ghent University Hospital1 papers (2022–2022)Katie Steenackers · University of Antwerp1 papers (2022–2022)Johan Van Cleemput · KU Leuven1 papers (2020–2020) · 1 papers (2022–2022)